|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Management of early gastrointestinal neuroendocrine neoplasms显示文摘Neuroendocrine neoplasms (NENs) of the stomach, duo- denum, appendix or rectum that are small (≤ 1 cm) and well differentiated can be considered 'early' tumors, since they generally have a (very) good prognosis. In the new WHO classification of 2010, these neoplasms are called neuroendocrine tumors/ carcinoids (NETs), grade (G) 1 or 2, and distinguished from poorly differentiated neuroendocrine carcinomas (NECs), G3. NETs are increasing, with a rise in the age-adjusted incidence in the U.S.A. by about 700 % in the last 35 years. Improved early detection seems to be the main reason for these epidemiological changes. Both the better generalavailability of endoscopy, and imaging techniques, have led to a shift in the discovery of smaller-sized (≤ 10-20 mm) intestinal NETs/carcinoids and earlier tumor stages at diagnosis. Endoscopic screening is therefore effective in the early diagnosis, not only of colorectal adenocarcinomas, but also of NETs/carcinoids. Endoscopic removal, followed up with endoscopic surveillance is the treatment of choice in NETs/carcinoids of the stomach, duodenum and rectum that are ≤ 10 mm in size, have a low proliferative activity (G1), do not infiltrate the muscular layer and show no angioinvasion. In all the other intestinal NENs, optimal treatment generally needs surgery and/or medical therapy depending on type, biology and stage of the tumor, as well as the individual situation of the patient. | Hans Scherübl Robert T Jensen Guillaume Cadiot Ulrich Stlzel Günter Klppel | 2011 | World Journal of Gastrointestinal Endoscopy2011，3，7： | 13 |
| 2 | Neuroendocrine tumors of the small bowels are on the rise:Early aspects and management显示文摘Neuroendocrine tumors of the small bowel are on the rise. In the US they have increased by 300%-500% in the last 35 years. At the same time their prognosis is much improved. Today,most neuroendocrine tumors (NETs) of the duodenum are detected 'incidentally' and therefore recognized at an early stage. Duodenal NETs which are well differentiated,not larger than 10 mm and limited to the mucosa/submucosa can be endoscopically resected. The management of duodenal NETs ranging between 10 and 20 mm needs an interdisciplinary discussion. Endoscopic ultrasound is the method of choice to determine tumor size and depth of infiltration. Surgery is recommended for well-differentiated duodenal NET tumors greater than 20 mm,for localized sporadic gastrinomas (of any size) and for localized poorly differentiated NE cancers. Surgery is recommended for any ileal NET. Advanced ileal NETs with a carcinoid syndrome are treated with longacting somatostatin analogs. This treatment significantly improves (progression-free) survival in patients with metastatic NETs of the ileum. For optimal NET management,tumor biology,type,localization and stage of the neoplasm,as well as the patient's individual circumstances have to be taken into account. | Hans Scherbl Robert T Jensen Guillaume Cadiot Ulrich Stlzel Gnter Klppel | 2010 | World Journal of Gastrointestinal Endoscopy2010，2，10： | 10 |
| 3 | Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors显示文摘 | Martyn E. Caplin Marianne Pavel Jaros?aw B. ?wik?a Alexandria T. Phan Markus Raderer Eva Sedlá?ková Guillaume Cadiot Edward M. Wolin Jaume Capdevila Lucy Wall Guido Rindi Alison Langley Séverine Martinez Jo?lle Blumberg Philippe Ruszniewski | 2014 | The New England Journal of Medicine2014，，： | 3 |
| 4 | Diagnosis of Zollinger-Ellison syndrome:Increasingly difficult显示文摘In the present paper the increasing difficulty of diag-nosis of Zollinger-Ellison syndrome (ZES) due to issues raised in two recent papers is discussed. These issues involve the difficulty and need to withdraw patients suspected of ZES from treatment with Proton Pump Inhibitors (omeprazole, esomeprazole, lansoprazole, rabeprazole, pantoprazole) and the unreliability of many gastrin radioimmunoassays. The clinical context of each of these important issues is reviewed and the conclusions in these articles commented from the per-spective of clinical management. | Tetsuhide Ito Guillaume Cadiot Robert T Jensen | 2012 | World Journal of Gastroenterology2012，18，39： | 3 |
| 5 | Saccharomyces boulardii Does Not Prevent Relapse of Crohn’s Disease显示文摘 | Arnaud Bourreille Guillaume Cadiot Gérard Le Dreau David Laharie Laurent Beaugerie Jean–Louis Dupas Philippe Marteau Patrick Rampal Dominique Moyse Ashraf Saleh Marie–Emmanuelle Le Guern Jean–Paul Galmiche | 2013 | Clinical Gastroenterology and Hepatology2013，，8： | 3 |
| 6 | ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor Syndromes显示文摘 | Jensen Robert T Cadiot Guillaume Brandi Maria L De Herder Wouter W Kaltsas Gregory Komminoth Paul Scoazec Jean-yves Salazar Ramon Sauvanet Alain Kianmanesh Reza | 2012 | Neuroendocrinology2012，，2： | 3 |
| 7 | Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems?显示文摘 | H. Scherübl G. Cadiot R. Jensen T. R?sch U. St?lzel G. Kl?ppel | 2010 | Endoscopy2010，，08： | 3 |
| 8 | Well-differentiated gastric tumors/carcinomas显示文摘 | Ruszniewski P Delle Fave G Cadiot G | 2006 | Neuroendocrinology2006，84，3： | 1 |
| 9 | Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems?显示文摘 | H. Scherübl G. Cadiot R. Jensen T. R?sch U. St?lzel G. Kl?ppel | 2010 | Endoscopy2010，，08： | 1 |
| 10 | Lower control arm rear bushing development an integrated approach显示文摘 | Stephem William Hope Gustavo Nunes Pinto Villela Conrado Alexandre de Paula Pinto Joao Luis Corradini Quaglia Dominique Cadiot Charles Pintos | 2003 | SAE2003，，： | 1 |
| 11 | ENETS Consensus Guidelines for the management of patients with digestive neuro- endocrine neoplasms: functional pancreatic endocrine tumor syndromes 显示文摘 | Jensen RT Cadiot G Brandi ML | 2012 | Neuroendocrinology2012，95，2： | 1 |
| 12 | Faecal calprotectin and magnetic resonance imaging in detecting Crohn's disease endoscopic postoperative recurrence显示文摘AIM To assess magnetic resonance imaging(MRI) and faecal calprotectin to detect endoscopic postoperative recurrence in patients with Crohn's disease(CD).METHODS From two tertiary centers, all patients with CD who underwent ileocolonic resection were consecutively and prospectively included. All the patients underwent MRI and endoscopy within the first year after surgery or after the restoration of intestinal continuity [median = 6 mo(5.0-9.3)]. The stools were collected the day before the colonoscopy to evaluate faecal calprotectin level. Endoscopic postoperative recurrence(POR) was defined as Rutgeerts' index ≥ i2b. The MRI was analyzed independently by two radiologists blinded from clinical data.RESULTS Apparent diffusion coefficient(ADC) was lower in patients with endoscopic POR compared to those with no recurrence(2.03 ± 0.32 vs 2.27 ± 0.38 × 10^(-3) mm^2/s, P = 0.032). Clermont score(10.4 ± 5.8 vs 7.4 ± 4.5, P = 0.038) and relative contrast enhancement(RCE)(129.4% ± 62.8% vs 76.4% ± 32.6%, P = 0.007) were significantly associated with endoscopic POR contrary to the magnetic resonance index of activity(Ma RIA)(7.3 ± 4.5 vs 4.8 ± 3.7; P = 0.15) and MR scoring system(P = 0.056). ADC < 2.35 × 10^(-3) mm^2/s [sensitivity = 0.85, specificity = 0.65, positive predictive value(PPV) = 0.85, negative predictive value(NPV) = 0.65] and RCE > 100%(sensitivity = 0.75, specificity = 0.81, PPV = 0.75, NPV = 0.81) were the best cutoff values to identify endoscopic POR. Clermont score > 6.4(sensitivity = 0.61, specificity = 0.82, PPV = 0.73, NPV = 0.74), Ma RIA > 3.76(sensitivity = 0.61, specificity = 0.82, PPV = 0.73, NPV = 0.74) and a MR scoring system ≥ MR1(sensitivity = 0.54, specificity = 0.82, PPV = 0.70, and NPV = 0.70) demonstrated interesting performances to detect endoscopic POR. Faecal calprotectin values were significantly higher in patients with endoscopic POR(114 ± 54.5 μg/g vs 354.8 ± 432.5 μg/g; P = 0.0075). Faecal calprotectin > 100 μg/g demonstrated high performances to detect endoscopic POR(sensitivity = 0.67, specificity = 0.93, PPV = 0.89 and NPV = 0.77).CONCLUSION Faecal calprotectin and MRI are two reliable tools to detect endoscopic POR in patients with CD. | Pierre Baillet Guillaume Cadiot Marion Goutte Felix Goutorbe Hedia Brixi Christine Hoeffel Christophe Allimant Maud Reymond Hélène Obritin-Guilhen Benoit Magnin Gilles Bommelaer Bruno Pereira Constance Hordonneau Anthony Buisson | 2018 | World Journal of Gastroenterology2018，24，5： | 1 |
| 13 | Expression of hepatocyte growth factor and its receptor,c-Met in human digestive tissues and different gastric and colonic cancer cell lines显示文摘 | Kermorgant S Cadiot G Lewin MJ etal | 1996 | Gastroenterol Clin Biol1996，20，5： | 1 |
| 14 | ENETS Consensus Guidelines for the management of patients with digestive neuro- endocrine neoplasms: functional pancreatic endocrine tumor syndromes 显示文摘 | Jensen RT Cadiot G Brandi ML | 2012 | Neuroendoerinology2012，95，2： | 1 |
| 15 | Well-differentiated gas-tric tumors/carcinomas显示文摘 | Ruszniewski P Delle Fave G Cadiot G | 2006 | Neuroendocrinology2006，84，3： | 1 |
| 16 | Detection of Hepatic Metastases from Carcinoid Tumor: Prospective Evaluation of Contrast-Enhanced Ultrasonography显示文摘 | Christine Hoeffel Louis Job Viviane Ladam-Marcus Fabien Vitry Guillaume Cadiot Claude Marcus | 2009 | Digestive Diseases and Sciences2009，，9： | 1 |
| 17 | ENETS consensus guidelines for the management of patients with digestive neuroen- docrine neoplasms: functional pancreatic endocrine tumor syn- dromes 显示文摘 | Jensen RT Cadiot G Brandi ML | 2012 | Neuroendocrinology2012，95，2： | 1 |
| 18 | Preeoperative detection of duodenal gastrinomas and pancreatic lymph nodes by somatostat in receptor scintigraphy 显示文摘 | Cadiot G Leatahir I R Sarada L | 1996 | Gastroenterology1996，111，4： | 1 |
| 19 | Well-differentiated gastric tumors/carcinomas显示文摘 | Ruszniewski P Delle Fave G Cadiot G | 2006 | Neuroendocrinology2006，84，3： | 1 |
| 20 | ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor Syndromes显示文摘 | Jensen Robert T Cadiot Guillaume Brandi Maria L De Herder Wouter W Kaltsas Gregory Komminoth Paul Scoazec Jean-yves Salazar Ramon Sauvanet Alain Kianmanesh Reza | 2012 | Neuroendocrinology2012，，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员